Related Experiment Video
Updated: Jun 2, 2026
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
What is the indication for sorafenib in hepatocellular carcinoma? A clinical challenge
Richard Kim1, Michael T Byrne, Ann Tan
1Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center, Tampa, Florida 33612, USA. Richard.Kim@moffitt.org
Abstract:
The incidence of hepatocellular carcinoma is rising in many countries, including the United States. Approval of sorafenib (Nexavar) as the first targeted therapy for treatment of advanced hepatocellular carcinoma (HCC) represents a milestone in the treatment of this disease. The approval was based on two large randomized phase III trials from the Western and Eastern hemispheres that showed an overall survival benefit compared with placebo in patients with well-preserved liver function. The exact indication for sorafenib is unclear, however. The U.S. Food and Drug Administration (FDA) authorized use of sorafenib for "unresectable HCC", an indication which is very broad, vague, and confusing. Less is known about the effects of sorafenib in patients with decompensated liver disease, or of sorafenib in combination with local therapy or in a transplant setting. Prospective trials are lacking in these areas. We will review current data on use of sorafenib in HCC.
Insights
Sorafenib is the first targeted therapy for advanced hepatocellular carcinoma (HCC), showing survival benefits in patients with good liver function. Its exact use, especially in complex cases, requires further investigation.
Area of Science:
- Oncology
- Hepatology
Background:
- Hepatocellular carcinoma (HCC) incidence is increasing globally.
- Sorafenib (Nexavar) is the first targeted therapy approved for advanced HCC.
- Approval was based on trials showing survival benefit in patients with preserved liver function.
Purpose of the Study:
- To review current data on sorafenib use in HCC.
- To clarify the indications for sorafenib in HCC treatment.
- To identify gaps in knowledge regarding sorafenib in specific patient populations.
Main Methods:
- Review of existing clinical trial data.
- Analysis of sorafenib efficacy and safety in advanced HCC.
- Assessment of sorafenib's role in various clinical settings.
Main Results:
- Sorafenib demonstrated an overall survival benefit compared to placebo in phase III trials.
- The approved indication for "unresectable HCC" is broad and lacks specificity.
- Limited data exists for sorafenib in decompensated liver disease, combination therapy, or transplant settings.
Conclusions:
- Sorafenib represents a significant advancement in HCC treatment.
- Further prospective trials are needed to define sorafenib's optimal use.
- Clarification of sorafenib indications is crucial for effective patient management.
More Related Videos
12:24A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
07:25Development and Optimization of A Human Hepatocellular Carcinoma Patient-Derived Organoid Model for Potential Target Identification and Drug Discovery
Published on: August 18, 2023
